La Asociación Española de Laboratorios de Medicamentos de Huérfanos y Ultrahuérfanos (AELMHU) ha incorporado a su lista de socios a Amicus Therapeutics SLU y Kyowa Kirin Farmacéutica, S.L.U., dos compañías biotecnológicas centradas en investigar y promover terapias para mejorar la situación de los pacientes que padecen enfermedades raras y ultra-raras en España.

Amicus Therapeutics is an American biotechnology company at the forefront of rare disease research with a portfolio of advanced therapies for a wide range of human genetic diseases, primarily lysosomal storage diseases.

Kyowa Kirin Co., Ltd. is a research-based company with a specific focus on biotechnology, headquartered in Japan and established in Europe and the United States. Its research areas are focused on Oncology, Immunology and in-house production of Monoclonal Antibodies with application in the treatment of certain rare diseases without current treatment and with unmet therapeutic needs.